Knockout studies in mice have shown that GSNOR regulates the smooth muscle tone in airways and the function of E-adrenergic receptors in lungs and heart. GSNOR has emerged as a target for the development of therapeutic approaches for treating lung and cardiovascular diseases.
S-nitrosoglutathione reductase (GSNOR) is an alcohol dehydrogenase involved in the regulation of s-nitrosothiols (SNOs) in vivo.
Knockout studies in mice have shown that GSNOR regulates the smooth muscle tone in airways and the function of E-adrenergic receptors in lungs and heart. GSNOR has emerged as a target for the development of therapeutic approaches for treating lung and cardiovascular diseases.
We report three compounds that exclude GSNOR substrate, Snitrosoglutathione (GSNO) from its binding site in GSNOR and cause an accumulation of SNOs inside the cells. The new inhibitors selectively inhibit GSNOR among the alcohol dehydrogenases.
Using the inhibitors we demonstrate that GSNOR limits nitric oxide (NO) mediated suppression of NF-NB and activation of soluble guanylyl cyclase (sGC). Our findings reveal GSNOR inhibitors to be novel tools for regulating NO bioactivity and assessing the role of SNOs in vivo.
S-nitrosylation of cellular proteins has emerged as the key reaction through which NO controls the function of a wide array of cellular proteins (1) . Through s-nitrosylation, NO has been shown to regulate smooth muscle tone, apoptosis, and NF-NB activity (2) (3) (4) (5) . Whereas snitrosylation mediates many of NO effects inside the body, denitrosylation pathways inside the cells terminate these effects. Among the enzymes capable of denitrosylating SNOs (6) (7) (8) (9) , the ubiquitously expressed, GSNOR has been shown to be operative in vivo (10;11) .
GSNOR, a member of the alcohol dehydrogenase family (12) , indirectly regulates SNOs inside the cells by reducing GSNO, a NO metabolite arising from the reaction of glutathione with reactive nitrogen species (11) . Owing to its role in the turnover of nitrosylation of intracellular proteins, GSNOR has become an important target for developing agents that modulate NO bioactivity inside cells. The therapeutic potential of preventing the breakdown of SNOs via inhibition of GSNOR has been demonstrated in mice lacking GSNOR. GSNOR deficient mice showed significantly low airway hyperresponsivity to allergen challenge and increased E-adrenergic receptor expression and function in lungs and heart (4;5) . This suggested GSNOR inhibition to be beneficial for the treatment of lung and cardiovascular diseases.
We report here, novel inhibitors of GSNOR which exclude GSNO from its binding site and preferentially inhibit GSNOR among the alcohol dehydrogenase (ADH) isozymes. Using the new inhibitors we demonstrate that GSNOR actively regulates s-nitrosylation of proteins stemming from nitric oxide synthase activity.
2 human GSNOR, ADH1B (E 2 E 2 -ADH), ADH4 (S-ADH), and ADH7 (V-ADH) were expressed in E.coli and purified in the Indiana University School of Medicine Protein Expression Core. Compounds C1-C3 were purchased from ChemDiv Inc. High throughput Screening: The screening for GSNOR inhibitors was performed using a library of 60,000 compounds from ChemDiv Inc in the Chemical Genomics Core facility at Indiana University. Screening was conducted in 384 well plates and involved incubating GSNOR with 12.5 PM compound, 1 mM each of NAD + and octanol in 0.1 M sodium glycine pH 10. Enzyme activity was determined by measuring the rate of production of NADH spectrophotometrically at 340 nm. Inhibition of GSNOR was calculated from the ratio of enzyme activity in the presence of compounds to that in no compound controls performed on the same plate. Following their identification from the high-throughput screening, the GSNOR inhibitory properties of the initial hits were confirmed at the pH 10 using octanol as the substrate and at pH 7.5 using GSNO as the substrate (see legend of Table 1 for details of the assay).
Inhibition of ADH isozymes by the C1-C3:
Inhibition of the ADH1B (E 2 E 2 -ADH), ADH4 (S-ADH), and ADH7 (V-ADH) was evaluated by determining the inhibitory effect of GSNOR inhibitors on the rate of oxidation of ethanol by each of these ADH isozymes. The assay mixture contained saturating amount of NAD + (1-2 mM) and ethanol at its K M concentration for each of the respective enzyme. All assays were performed at 25 ºC in 50 mM potassium phosphate pH 7.5 containing 0.1 mM EDTA and involved determining the rate of formation of NADH spectrophotometrically at 340 nm. Specific assay conditions for each isozyme are as follows: a) Studies with ADH1B (E 2 E 2 -ADH) involved adding 3.5 Pg of the enzyme to the assay mixture containing 2 mM NAD + , 1 mM ethanol and the inhibitor; b) Studies with ADH7 (VV-ADH) involved adding 0.5 Pg of enzyme to the assay mixture containing 2 mM NAD + , 30 mM ethanol and the inhibitor; c) Studies with ADH4 (S-ADH) involved adding 19.5 Pg of the enzyme to the assay mixture containing 1 mM NAD + , 35 mM ethanol and the inhibitor; and d) Studies with GSNOR involved adding 0.1 Pg of the enzyme to an assay mixture containing 15 PM NADH, 5 PM GSNO and the inhibitor.
Dead-end inhibition studies:
Inhibition experiments with the GSNOR inhibitors were conducted at 25 ºC in 3 ml of 50 mM potassium phosphate (pH 7.5) containing 0.1 mM EDTA. Five different concentrations of GSNO or NADH were used when they were the varied substrates and maintained at 10 and 15 PM, respectively, when present as the nonvaried substrate. A minimum of three inhibitor concentrations were used and the rate of NADH and GSNO consumption determined spectrophotometrically at 340 nm. The data were fit to the competitive, noncompetitive and uncompetitive inhibition models and the model best fitting the data was chosen on the basis of F-statistics performed using the Graphpad Prizm 4.0. Fluorescence studies: Fluorescence studies were conducted in 50 mM potassium phosphate pH 7.5, at room temperature using a Fluoromax-2 fluorescence spectrometer (Instruments S.A., Inc., Edison, NJ).The equilibrium dissociation constant of GSNOR inhibitors was determined by measuring the changes in the fluorescence of GSNOR bound NADH (Ȝ exc = 350 nm; Ȝ emm = 455 nm) upon the addition of inhibitor. During the experiment, increasing amounts of inhibitor were added to a solution containing 2 PM GSNOR and 1.7 PM NADH. The decrease in fluorescence at 455 nm with each addition of inhibitor was plotted against the final concentration of inhibitor and the data were fitted to equation 1 using nonlinear regression to obtain the dissociation constant of the inhibitor for GSNOR-NADH complex,
(1) In equation 1, ¨F is the change in the fluorescence at 455 nm upon the addition of inhibitor. ¨F M is the maximum fluorescence change that was obtained from curve fitting. E T and L T , are the concentrations of GSNOR and inhibitor, respectively. K D is the equilibrium dissociation constant for the formation of GSNOR•NADH•Inhibitor complex.
The data were fitted using the Graphpad Prizm 4.0.
Determination of nitroso species accumulation in RAW cells using the triiodide based chemiluminescence method: RAW 264.7 cells were cultured in DMEM medium supplemented with 10 % FBS, 200 U/ml penicillin and 200 Pg/mL streptomycin. The cells were incubated at 37 ºC in an atmosphere containing 5% CO 2 and 95% air. For the experiments, 1-2 X 10 6 cells were plated in six-well plates with or without 33 PM compounds, 16 hours before the experiment (Later experiments showed that pretreatment with compounds had no effect on the rate of accumulation of nitrosospecies inside the cells). On the day of experiment the medium was replaced with fresh 3 ml of medium and the cells were treated with compounds for a predetermined length of time. Following the incubation period, the cells were washed three times with PBS and scraped off the plate in 250 Pl of lysis buffer (50 mM potassium phosphate pH 7.0 containing 50 mM NEM and 1mM EDTA) and lysed by sonication using a micro tip probe ( three pulses of 30% duty cycle; 2 output control on a Branson Sonicator).
The cell debri was pelleted by centrifugation (10 min at 16,000g) and the cell lysate was analyzed for protein concentration using the Bio-Rad dye-binding protein assay. The concentration of nitroso compounds in the cell lysate was determined using the triiodide based chemiluminescence method using a Sievers 280 nitric oxide analyzer. Briefly, cell lysates were treated with 15% v/v of a sulfanilamide solution (5 % w/v in 0.2 M HCl) and kept at room temperature for 5 min to remove nitrite. The triiodide mixture was prepared fresh every day as described earlier and kept at 60 ºC in the reaction vessel. The concentration of nitroso species was derived from a standard curve generated using GSNO. S-nitrosothiol detection in RAW 264.7 cells using the biotin switch assay: RAW 264.7 cells were cultured in 100 mm dishes using DMEM medium containing 10% heat-inactivated serum and 100 units/ml penicillin, 100Pg/ml streptomycin. On the day of the experiment, the media was replaced with a fresh medium containing C3 (33 PM) alone or a mixture of C3 and L-NAME (1.1 mM) and the cells were incubated at 37 °C for varied lengths of time. At indicated times, the cells were quenched and the lysate was analyzed for s-nitrosothiol content by the biotin switch assay as described by Jaffrey et al (13) with modifications suggested by Wang et al (14) and Zhang et al (15) . Briefly, free sulfydryls in ~200 Pg of cell lysate were blocked with 20 mM MMTS in 1 ml of HEN buffer (250 mM HEPES pH 7.7 containing 1 mM EDTA and 0.1 mM Neocupronine) containing 2% SDS at 50 °C for 20 min. Free MMTS was removed by gelfiltration spin columns and the blocked proteins were labeled with 1 mM Biotin-HPDP (Pierce) in presence or absence of 30 mM ascorbate and 2 PM CuCl for 3 hours. Equal amounts of proteins were loaded in each lane and the degree of biotinylation (and hence s-nitrosylation) determined using an anti-biotin antibody (SIGMA).
For the isolation of biotinylated proteins, equal amounts of biotinylated RAW cell extract were treated with streptavidin agarose and incubated at 4 °C for 4hrs. The resin was extensively washed with a washing buffer (25 mM HEPES pH 7.7 containing 600 mM NaCl, 1 mM EDTA, and 1% E-octyl glucoside) before eluting them using SDS-PAGE sample buffer containing 500 mM E-mercaptoethanol at 40 °C for 2 hrs. The eluted proteins were separated using SDS-PAGE and blotted onto a PVDF membrane. The blots were probed with IKKȕ antibody (Cell Signaling Technology) and immunodetected by chemiluminescence. A549 Luciferase Reporter Assay. A549/NfNBluc cells (Panomics, Quantitative Biology, ) harboring a luciferase reporter under the control of six consensus NF-NB binding motifs were propagated at 37 °C in presence of 5% CO 2 and in DMEM Medium with 100 units/ml penicillin, 100Pg/ml streptomycin and 10% heat inactivated fetal bovine serum. During the experiments, 10 5 cells were plated with 2 ml medium and 100 Pg/ml hygromycin in 12 well plates. Cells were treated with C3 for 4 hrs followed by TNFD (50 ng/ml) treatment for 6 hrs. Luciferase activity was measured in cell lysates using a commercial kit (Promega, Madison, WI). The luciferase activity was measured using a manual luminometer and the data was normalized to the total protein concentration determined using the BCA protein assay. Western blots. A549 or RAW 264.7 cells, were cultured respectively in F-12k or DMEM medium containing 10% heat-inactivated serum and 100 units/ml penicillin and 100 mg/ml streptomycin. A549 (2 x 10 5 ) and RAW 264.7 (2.5 x 10 5 ) were plated in 35 mm plates or 50,000 A549 cells were plated in 24-well plates on the day before the experiment. On the day of the experiment, the medium was replaced with fresh medium plus or minus varied concentrations of C3 for 4 hrs. In some experiments, the cells were also treated with MG132 (40 PM final) for 1hr. Following the pretreatments, the cells were treated with TNFD (10 ng/ml) for 5 minutes for the analysis of phospho-IțBĮ, IțBĮ, phospho-IKKĮ/ȕ, IKKE and for 6 h for analysis of ICAM-1 before quenching them with SDS-PAGE sample buffer containing 50 mM NaF. Samples were vortexed, boiled for 5 minutes centrifuged at 16000 x g for 5 minutes and loaded onto a 10% precast SDSpolyacrylamide Tris-HCl gel (Bio-Rad, CA) and transferred to a PVDF membrane. The blots were probed overnight with primary antibodies at 4 °C and incubated with the appropriate HRP conjugated secondary antibodies for 1 hour at RT. The signal was detected using GE Healthcare ECL Plus chemiluminescence kit. Wire myography: Mice were anesthetized with diethyl ether. A thoracotomy was performed to expose thoracic and abdominal aorta. A 25 gauge syringe was inserted into the apex of left ventricle and perfused free of blood with oxygenated Krebs Henseleit buffer. The right atrium was cut to provide an exit for blood. The aorta was removed and cleaned of fat and adventitia. The aorta was cut into 2-mm-long segments and mounted on a four-channel wire myograph (AD Instruments). Vessel rings were maintained in 10-ml organ baths with oxygenated PSS (95% O 2 and 5% CO 2 ) at 37 °C. Rings were allowed to equilibrate for 80 minutes with the buffer in each organ bath changed every 20 min. One gram pretension was placed on each aortic ring (appropriate starting tension for optimal vasomotor function as determined in previous experiments). An eightchannel octal bridge (Powerlab) and dataacquisition software (Chart version 5.2.2) were used to record all force measurements. After equilibration for 80 min, 1μM phenylephrine was added to each ring for submaximal contraction. After stabilization, either C3 or sodium nitroprusside (SNP) was added to the rings and the tone of the rings determined.
For the determination of SNP and ACh dose-response relationships, aortic rings were precontracted with 10 -6 M PE, and SNP or C3 was then added in increasing concentrations from 10 -9 M to 10 -4 M. Soluble guanylyl cyclase assay: Cytosolic fraction of RAW264.7 cells (20 uL) was mixed with 40 ul of reaction buffer ( 50 mM TEA pH7.4, 0.1 mM EGTA, 0.1 mg/ml creatine kinase, 200 ȝM phosphocreatine, 100 ȝM cGMP) and when necessary supplied with 50 ȝM C3 and incubated for 10 minutes at room temperature. The samples were then supplied with 50 ȝM GSNO and incubated for additional 10 minutes. At the end of incubation, 0.3 ȝg of purified sGC was added to the sample, which was transferred to 37 o C and the cyclase reaction was initiated by 1 mM GTP/[ĮP 32 ]-GTP. After 10 minutes the reaction was stopped by 0.5 ml 150 mM Zn acetate followed by addition of 0.5 ml of 200 mM sodium carbonate. The formed Zn carbonate pellet containing the bulk of unreacted GTP was precipitated by 10 minute centrifugation at 15,000xg and the supernatant was loaded on 1 ml alumina oxide column equilibrated with 50 mM Tris pH 7.5. cGMP was eluted from the column with 10 ml 50 mM Tris pH 7.5, collected and quantified by scintillation counter.
Results:

Identification of compounds that specifically inhibit GSNOR:
A high-throughput screening approach was used for identifying novel inhibitors of GSNOR. Screening for GSNOR inhibitors was performed in the presence of saturating and unsaturating concentrations of NAD + and the alcohol substrate, octanol (16) , to increase the probability of identifying compounds that bind only in the GSNO binding site of GSNOR. Three compounds (C1-C3) displaying high affinity and specificity for inhibiting GSNOR within the alcohol dehydrogenase family were selected for further investigation (Tables 1 and S1 ). Each of the selected compounds obeyed Lipinski's rules (17) for drug-like properties and had two orders of magnitude lower IC 50 than the present GSNOR inhibitor, dodecanoic acid (18) ( Table 1) .
Dead-end kinetic inhibition and fluorescence binding studies were performed to determine the mechanism by which C1-C3 inhibited GSNOR. As evident from Table 2 and This suggested that neither of the substrates were able to completely prevent the compounds from binding to GSNOR. The inability of both the substrates to overcome the inhibition completely is also consistent with C1-C3 binding to multiple enzyme complexes in the kinetic pathway (shown in scheme 1). Inhibition by binding to a site outside the active site in GSNOR was unlikely since the type of inhibition by the compounds against NADH and GSNOR would have been similar. An additional dead-end inhibition study involving dodecanoic acid as inhibitor against varied GSNO was performed to determine the type of complexes that an inhibitor binding in the substrate binding site (18;19) would form in the kinetic pathway of GSNO reduction. Dodecanoic acid was found to be a noncompetitive inhibitor against varied concentrations of GSNO even though it binds into the GSNO binding site ( Table  2 ). The noncompetitive inhibition of GSNOR by dodecanoic acid can be explained by its binding to GSNOR at more than one place in the kinetic pathway; one where it competes with GSNO to bind to the enzyme (steps 1 and 2 in scheme 1) and one where GSNO does not normally bind in the kinetic pathway (step 3 in scheme 1).
The noncompetitive inhibition of GSNOR by C1-C3 against varied GSNO can also be explained by their forming such E•NADH•I (EAI in scheme 1) and E•NAD + •I (EQI in scheme 1) complexes. The uncompetitive inhibition by C1 and C3 and almost uncompetitive inhibition by C2 (although inhibition by C2 statistically fits noncompetitive mechanism better, the K is is five fold higher than K ii and has high standard errors) against varied NADH can be explained by the compounds binding to the E•NADH complex in the nearly ordered kinetic mechanism of GSNOR and the high affinity of NADH (K D = 0.05 PM) for GSNOR (18) . Both these factors would make the contribution of E•I very small in the inhibition of the enzyme under the experimental conditions and make the inhibition uncompetitive.
The mechanism by which C1-C3 inhibits GSNOR is similar to that by which the sulfoxide and amide compounds inhibit horse liver alcohol dehydrogenase (20) . To summarize, the dead-end kinetic inhibition studies are consistent with C1- Figure 1C) .
The equilibrium dissociation constants of C1-C3 were in the low micromolar range (Table 2) suggesting the affinity for the GSNOR•NADH complex was sufficient for the compounds to be effective inside the cells. C1 and C3 had a significantly higher affinity for the GSNOR•NADH complex than C2 as evident from their 3-5 fold lower equilibrium dissociation constants.
The ability of the newly discovered inhibitors to inhibit GSNOR inside the cells was tested using a murine macrophage cell line (RAW 264.7 cells). RAW 264.7 cells were treated with inhibitors alone or in combination with GSNO. The accumulation of intracellular SNOs was determined as a function of time and inhibitor concentration ( Fig. 2A and 2B) . Significantly higher amounts of SNOs accumulated in cells treated with both GSNO and the inhibitor than in those treated with GSNO alone (Fig. 2A) . C1 and C3 appeared to be more effective than C2 in inhibiting GSNOR inside the cells as evident from higher accumulation of SNOs ( Fig. 2A and 2B ). These studies demonstrate that C1-C3 are able to inhibit intracellular GSNOR. The dependence of SNO accumulation on the concentration of compounds in RAW 264.7 cells (Fig 2B) suggested that it was possible to regulate the extent of S-nitrosylation with the GSNOR inhibitors. An analysis of the molecular size of the nitrosylated species inside the treated cells showed that more than 95% of the nitrosylated species were greater than 5 kDa in size. Furthermore, 21-28 % of the nitrosylated species in treated cells were resistant to mercury pretreatment, suggesting that N-nitrosothiolated proteins were also getting formed inside the cells.
The effect of GSNOR inhibition on the nitrosylation of cellular proteins was also examined using the biotin switch assay technique developed by Jaffrey et al (22) with modifications by Wang et al (23) . C3 increased the nitrosylation of cellular proteins in RAW 264.7 cells, in a timedependent manner (Fig. 2C) . The effects of C3 on the nitrosylation of cellular proteins appeared to peak around 8 hours before coming down. The accumulation of SNOs was less if cells were simultaneously treated with C3 and the nitric oxide synthase inhibitor, L-NAME (Fig. 2C) . These data suggested that the accumulation of SNOs in GSNOR inhibited cells is dependent on NOS function and activity. The accumulation of SNOs in GSNOR inhibited cells suggested that the inhibitors could be used to identify cellular processes regulated by GSNOR. The effects of GSNOR inhibition on two processes reported to be regulated by s-nitrosylation were examined. The effects of C3 on the activation of NF-kB by TNFD in cultured cells and on the tone of murine aorta were studied.
Suppression of NFNB activation by GSNOR inhibition
NF-NB is a master regulator of the inflammatory response and exists in an inactive form in the cytoplasm complexed with a protein called Inhibitor of kappa B (INB) (24) . Upon arrival of a wide variety of stimuli, a kinase, Inhibitor of kappa B kinase E (IKKE is activated by phosphorylation and in turn phosphorylates INB. Phosphorylated INB (p-INB) is targeted for ubiquitin dependent proteosomal degradation, setting NF-NB free to initiate the transcription of inflammatory genes (24) . Nitric oxide and NF-NB regulate each other's activity as evident from the presence of NF-NB response elements in NOS2 promoter region and the suppression of NF-NB activity by s-nitrosylation (3;25-27) . IKKE has been shown to be the most upstream target of NO mediated s-nitrosylation in the NF-NB signaling pathway (26) . S-nitrosylation of IKKE inhibits its kinase activity and suppresses NF-NB activation. To determine if IKKE was among the proteins undergoing s-nitrosylation in the presence of C3, we performed the biotin switch assay on the cytosolic proteins from RAW 264.7 cells treated with C3. The presence of a higher amount of biotinylated IKKE in the labeling mixture containing ascorbate vs the no ascorbate control (Fig. 3A) suggested that IKKE was S-nitrosylated in cells treated with C3. The s-nitrosylation of IKKE appeared to be dependent on the activity of nitric oxide synthases as co-incubation of the cells with C3 and nitric oxide synthase inhibitor, L-NAME decreased its nitrosylation (lane 4h+N vs 4h in Fig. 3A ). This result suggested that nitric oxide synthase products nitrosylate IKKE while GSNOR regulates the extent and turnover of snitrosylation of IKKE. Since nitrosylation of IKKE inhibits its kinase activity, the effect of C3 on the phosphorylation of INB by IKKE was studied. As evident in Fig. 3B , the amount of TNFD induced phosphorylation of INB was decreased in cells pretreated with C3. The extent of phosphorylation decreased further with increasing concentrations of C3. This suggested that the inhibition of IKKE increased with the extent of GSNOR inhibition.
We also studied the effect of C3 on the TNFD induced activation of IKKE and subsequently, NF-NB, in A549 lung epithelial cells (Figs. 3C-E, S2 and 4) . In a NF-NB reporter assay performed in A549 cells expressing luciferase under the control of six NF-NB response elements, C3 reduced the TNFD induced NF-NB activity in a dose-dependent manner (Fig. 3C) . Since the induction of NF-NB activity by TNFD is dependent upon IKKE activity (28), phosphorylation of INB was studied to determine if IKKE was inhibited in the A549 cells pretreated with C3.
The total amount of INB was significantly higher in cells pretreated with C3 (Fig. S2) , suggesting that the rate of degradation of INB was significantly lower in these cells. Lower amounts of phospho-INB were also found in cells treated with both, C3 and the proteasome inhibitor, MG132 (29) (Fig. 3D ). This suggested that the higher levels of INB observed in cells pretreated with C3 (Fig. S2 ) were due to a decrease in the rate of the phosphorylation of INB rather than a decrease in the rate of proteasomal phospho-INB degradation. Together, these results suggested that in C3 treated cells IKKE was inhibited. However, the observed suppression of NF-NB activation as measured in the luciferase assay could also have been potentiated by s-nitrosylation of the p65 and p50 subunits of NF-NB. S-nitrosocysteine has been reported to nitrosylate the p65 and p50 subunits of NF-NB and inhibit their transactivation property (3;30) .
We also examined the effects of C3 on the phosphorylation of IKKE and its kinase activity to rule out other mechanisms of inhibition of IKKE. As shown in Fig. 3E , the extent of IKKE phosphorylation was similar in cells treated with TNFD alone and those treated with C3 and TNFD. This suggested that C3 does not affect any of the proteins involved in the activation of IKKE by TNFD. C3 also had no significant effect on the kinase activity of IKKE ( Figure S3 ). This suggested that inhibition of IKKE did not result from any direct interaction between C3 and IKKE. Together, the data is consistent with the nitrosylation induced inhibition of IKKE in C3 treated cells.
The suppression of NF-NB activity by C3 in A549 cells was also studied by determining the amount of inter-cellular adhesion molecule-1 (ICAM-1) expressed in response to TNFD. ICAM-1 is one of the pro-inflammatory proteins induced by NF-NB (31) . C3 decreased the expression of ICAM-1 in response to TNFD in a dose dependent manner in A549 cells (Fig. 4) . This is consistent with the suppression of NF-NB mediated gene expression in C3 treated cells.
Relaxation of murine aorta by GSNOR inhibition:
Nitric oxide-dependent regulation of vascular tone is mediated through the activation of sGC (32). S-nitrosothiols, through decomposition to NO have been shown to mediate the activation of sGC and relax smooth muscles (33). Treatment with C3 (50μM) completely relaxed the preconstricted segments of murine aorta within 15 min (Fig. S4) . A complete concentration response curve revealed an EC 50 of 5μM for C3 (Fig. 5A) , with as little as 300 nM giving ~10% relaxation. Direct comparison with sodium nitroprusside (SNP) revealed that C3 was less potent than SNP at relaxing the vascular smooth muscle (Fig. 5A ). This suggested that GSNOR regulated snitrosothiols were involved in the regulation of vascular tone. To determine if stimulation of sGC was involved during the relaxation of aorta rings by C3, the effect of C3 on cGMP production by sGC was studied in vitro. Addition of GSNO to RAW 264.7 cell lysate supplemented with recombinant sGC resulted in a stimulation of cGMP production (Fig. 5B) . These data are consistent with an earlier report on the relaxation of smooth muscles by GSNO through the release of nitric oxide(34). In presence of C3, the stimulation of cGMP production by GSNO more than doubled, suggesting that GSNOR mediated decomposition of GSNO limits the amount of nitric oxide released from s-nitrosothiols for the stimulation of sGC.
Collectively these data demonstrate that inhibiting nitrosothiol breakdown activates and enhances the NO-cGMP pathway.
Discussion
The central role of s-nitrosylation in the cellular effects of nitric oxide is increasingly being realized as the reports of proteins regulated by snitrosylation continue growing. SNOs are both the end-products of nitric oxide signaling pathway as well as the carriers of nitric oxide. Regulating the levels of SNOs should regulate nitric oxide bioactivity. Our studies reveal that denitrosylation affected by GSNOR limits the NO mediated activation of guanylyl cyclase and the suppression of NF-NB. The three inhibitors described herein will allow determining the processes regulated by GSNOR through S-nitrosylation and allow examining the therapeutic benefit of inhibiting GSNOR. The suppression of NF-NB activation in RAW 264.7 and A549 cells and the relaxation of murine aorta by C3 suggest the possibility of regulating immune response and the tone of smooth muscles simultaneously via GSNOR inhibition. Similar to phosphodiesterase inhibitors such as sildenafil, the action of these compounds require some production of NO from NOS.
The accumulation of nitrosothiols in RAW 264.7 cells treated with C3 suggests GSNOR to be actively regulating the turnover and metabolism of s-nitrosothiols inside the cells. Owing to the large number of proteins shown to be affected by s-nitrosylation, and the number of enzymes shown to effect denitrosylation, the cellular effects of GSNOR inhibitors will depend on the identity of the proteins getting nitrosylated and the time period over which that occurs. It also became evident that the effects of the GSNOR inhibition are not immediate and the effect on the cellular processes correlates with the accumulation of s-nitrosylated protein(s) or release of NO from SNOs.
In case of suppression of NF-NB activation, pretreatment of the cells with the C3 was essential. Similarly, the relaxation of murine aorta by C3 occurred after a period of time. Thus, the effects of GSNOR inhibition are likely to come into effect slowly.
The exclusion of GSNO from its binding site and inhibition of GSNOR at multiple places in its kinetic pathway by C1-C3 is advantageous for the in vivo inhibition of GSNOR. GSNOR substrates would not be able to prevent C1-C3 from binding GSNOR and overcome inhibition. By virtue of not binding in the coenzyme binding site, C1-C3 have a high probability of specifically inhibiting GSNOR among the NAD(H) binding dehydrogenases. While being structurally diverse, C1-C3, each has a free carboxyl group like most substrates for GSNOR. Given the importance of Arg115 at the base of the GSNOR active site in the binding of GSNO and S-hydroxymethylglutathione (35;36), it is very likely that the free carboxyl group in C1-C3 interacts with Arg115. In summary, we report novel tools that regulate GSNOR function inside the cells that will allow exploring the cellular and pharmacological effects of inhibiting an important nitric oxide deactivation pathway. Kinetic mechanism of GSNOR and the types of complexes formed by dodecanoic acid and the new GSNOR inhibitors in the kinetic pathway of GSNOR. GSNOR has a preferred pathway (shown by the bold lines) through GSNOR•NADH complex (EA) in its random mechanism during the reduction of an aldehyde. The aldehyde (B), although can bind to the free form of GSNOR (E), binds preferentially to the GSNOR•NADH complex (EA) to form the competent ternary complex (EAB). The EAB complex undergoes catalysis to form the products, NAD + (Q) and alcohol (P). During the release of the products, either of the products can leave the enzyme. An inhibitor binding the GSNO binding site can bind to the free GSNOR (step 1), GSNOR•NADH (step 2) or GSNOR•NAD + (step 3) binary complexes to form EI, EAI and EQI complexes, respectively. 16 hours were transferred to a fresh medium containing 500 PM GSNO alone (Ƒ) or GSNO and 33 PM C1 (ż), C2 (¨) or C3 (Ŷ). At indicated times, the lysates were prepared and analyzed for nitroso species and protein concentration using the chemiluminescence and Bradford assays, respectively. Data corresponds to means ± SE (n=6-21 wells), and p< 0.0001 by t-test versus GSNO treated cells for all measurements except for cells treated with GSNO and C2 for 6 hours (p<0.01). (B) Effect of the increasing concentrations of the compounds on the buildup of nitrosylated species in RAW 264.7 cells. RAW 264.7 cells were incubated with 500 PM GSNO in presence of increasing concentrations of C1 (ż) or C2 (¨) or C3 (Ŷ). After 4 hours, cell lysates were prepared and analyzed for nitroso species and protein concentration. Data corresponds to means ± SE (n=3-6 wells). The concentration of the compounds used in the time-dependent experiment ( Fig. 2A) is shown by the arrow. (C) Regulation of S-nitrosylation in RAW 264.7 cells by GSNOR. RAW cells were treated with 33 ȝM C3 for varied lengths of time (0, 2, 4, 8 and 24 h) alone or in combination with 1.1 mM NAME for 4 h (lane 4+N). At indicated times, the cells were quenched and the lysate was analyzed for s-nitrosothiol content by the biotin switch assay. Equal amounts of proteins were loaded in each lane and the degree of biotinylation (and hence Snitrosylation) determined using an anti-biotin antibody. , 4h, 8h ) or in combination with 1.1 mM L-NAME for 4 hrs (4h+N) and analyzed for S-nitrosylation using the Biotin switch assay. Equal amounts of biotinylated cell extract from each sample were subjected to streptavidin purification and western blotted using IKKE antibody. The specificity of the biotin switch assay was demonstrated using no Ascorbate controls; B) Inhibition of TNFD induced phosphorylation of INB in RAW 264.7 cells in presence of C3. RAW 264.7 cells, were treated with varied concentrations of C3 (C3 -0, 30, 50, and 100 PM) for 4 hrs before being activated with TNFD (10 ng/ml) for 5 min. The cell extract was analyzed by western blot using p-INB and INB antibodies. Controls involving untreated cells (Ctrl) or those treated with 100 PM C3 alone were also performed concomitantly. The ratios (mean± SE) of the intensities of p-INB and INB is shown (n=3; **, p < 0.001). C) Suppression of NF-NB dependent gene transcription by C3 in A549 cells. A549 cells harboring a NF-NB dependent luciferase reporter were treated with varied concentrations of C3 (0, 10, 50 and 100 PM) for 4 hrs before being stimulated with TNFD (50 ng/ml) for 6 hrs. Following the incubation period, the cell extract was tested for luciferase activity and the mean (± SE) fold change in luciferase activity over untreated cells determined (n=4; *, p < 0.05; **, p < 0.001); D) Inhibition of TNFD induced activation of IKKE in A549 cells by C3. A549 cells were treated with indicated concentrations of C3 for 4 hrs in the presence of MG132 (1 hr incubation) before being activated with TNFD ng/mL for 5 min. The cell extract was subjected to western blot using p-INB, INB and GAPDH antibodies. The ratios (mean ± range; n=2) of the intensities of p-INB and INB is shown; E) C3 does not affect TNFD induced phosphorylation of IKKE in A549 cells. A549 cells, treated or untreated with indicated concentration of C3 for 4 hrs, were activated with TNFD for 5 mins and quenched for western blot analysis using p-IKKE antibody. . A549 cells, treated with varied concentrations of C3 for 4 hours were stimulated with TNFD (10 ng/mL) for 6 hrs before quenching the cells and analyzing the cell extract by western blot analysis using ICAM-1 and GAPDH antibodies. The band intensities of ICAM-1 and GAPDH were determined by densitometry. The graph shows the mean ± SE of the ratio (n=4; *, p < 0.05; **, p < 0.01). Mouse aorta segments were equilibrated in oxygenated PSS (95% O 2 and 5% CO 2 ) at 37 °C. Following equilibration, 1μM phenylephrine was added to each ring for submaximal contraction. After stabilization, increasing concentrations (0-100 ȝM) of either C3 or sodium nitroprusside (SNP) was added to the rings and the response to agonist was determined as percent of maximal relaxation. (B) C3 potentiates the activation of sGC by nitrosoglutathione. RAW cell lysate, which has GSNOR activity but lacks sGC, was supplied with recombinant sGC protein and preincubated for 10 minutes with 50 ȝM C3 or buffer. After the addition of 50 ȝM GSNO or PBS vehicle, GMP synthesis was measured by direct ĮP 32 -GTPAEcGMP conversion as described previously (37). 
